Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: BIO-key International Inc., 3 years.
BIO-key International Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
BIO-key International Inc. August 8, 202577.0%
-
BIO-key International Inc. August 22, 202478.9%
-
BIO-key International Inc. July 24, 202364.4%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 23, 2026 | Daxor Corporation | Grant or award | +12,000 | — | — |
| Mar 31, 2026 | Daxor Corporation | Open-market purchase | +1,000 | $9.90 | $9,900 |
| Dec 9, 2025 | Daxor Corporation | Open-market purchase | +3,000 | — | — |
| May 27, 2025 | BIO-key International Inc. | Grant or award | +5,000 | — | — |
| May 27, 2025 | BIO-key International Inc. | Grant or award | +1,266 | $0.79 | $1,000 |
| May 8, 2025 | BIO-key International Inc. | Grant or award | +3,897 | — | — |
| Mar 20, 2025 | BIO-key International Inc. | Grant or award | +2,971 | — | — |
| Mar 10, 2025 | Daxor Corporation | Open-market purchase | +1,000 | $8.00 | $8,000 |
| Nov 7, 2024 | BIO-key International Inc. | Grant or award | +2,587 | — | — |
| Jul 31, 2024 | BIO-key International Inc. | Grant or award | +3,500 | — | — |
| Jul 31, 2024 | BIO-key International Inc. | Grant or award | +676 | — | — |
| Mar 27, 2024 | BIO-key International Inc. | Grant or award | +1,429 | — | — |
| Mar 27, 2024 | Daxor Corporation | Open-market purchase | +750 | $8.70 | $6,525 |
| Dec 6, 2023 | Daxor Corporation | Open-market purchase | +120 | $7.75 | $930 |
| Dec 1, 2023 | Daxor Corporation | Open-market purchase | +180 | $7.75 | $1,395 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.